argenx SE(1AEA)

Description: argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

---

Keywords: Biotechnology Immunology Antibodies Autoimmune Disease Inflammation Autoimmunity Safety Systems Amyotrophic Lateral Sclerosis Lupus Myasthenia Gravis Immune Thrombocytopenia Chronic Inflammatory Demyelinating Polyneuropathy Thyroid Eye Disease Pemphigus Therapies For The Treatment Of Autoimmune Diseases Bullous Pemphigoid Dermatomyositis Leiden University Medical Center Nyu Pemphigus Vulgaris Anca Associated Vasculitis Argx 112 Membranous Nephropathy Myositis Pemphigoid Argx 109 Congenital Myasthenic Syndrome Efgartigimod Alfa Gravis Neonatal Fragment Crystallizable Receptor Post Covid Postural Orthostatic Tachycardia Syndrome Primary Sjögren's Syndrome Therapeutic Antibodies With Applications

---

Home Page: www.argenx.com

Laarderhoogtweg 25
Amsterdam, 1101EB
Netherlands
Phone: 31 10 703 8441

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)